BACKGROUND: Despite the availability of effective hypertension, hyperlipidemia, and hyperglycemia therapies, target levels of systolic blood pressure (SBP), LDL-cholesterol (LDL-c), and hemoglobin A1c control are often not achieved. OBJECTIVE: To examine the relative importance of patient medication nonadherence versus clinician lack of therapy intensification in explaining above target cardiovascular disease (CVD) risk factor levels. DESIGN: Cross-sectional assessment. PARTICIPANTS: In 2005, 161,697 Kaiser Permanente Northern California adult diabetes patients were included in the study. MEASUREMENT: "Above target" was defined as most recent A1c >/=7.0% for hyperglycemia, LDL-c >/=100 mg/dL for hyperlipidemia, and SBP >/=130 mmHg for hypertension. Poor adherence was defined as medication gaps for >/=20% of days covered for all medications for each condition separately. Treatment intensification was defined as an increase in the number of drug classes, increased dosage of a class, or a switch to a different class within the 3 months before or after notation of above target levels. RESULTS: Poor adherence was found in 20-23% of patients across the 3 conditions. No evidence of poor adherence with no treatment intensification was found in 30% of hyperglycemia patients, 47% of hyperlipidemia patients, and 36% of hypertension patients. Poor adherence or lack of therapy intensification was evident in 53-68% of patients above target levels across conditions. CONCLUSIONS: Both nonadherence and lack of treatment intensification occur frequently in patients above target for CVD risk factor levels; however, lack of therapy intensification was somewhat more common. Quality improvement efforts should focus on these modifiable barriers to CVD risk factor control.
BACKGROUND: Despite the availability of effective hypertension, hyperlipidemia, and hyperglycemia therapies, target levels of systolic blood pressure (SBP), LDL-cholesterol (LDL-c), and hemoglobin A1c control are often not achieved. OBJECTIVE: To examine the relative importance of patient medication nonadherence versus clinician lack of therapy intensification in explaining above target cardiovascular disease (CVD) risk factor levels. DESIGN: Cross-sectional assessment. PARTICIPANTS: In 2005, 161,697 Kaiser Permanente Northern California adult diabetespatients were included in the study. MEASUREMENT: "Above target" was defined as most recent A1c >/=7.0% for hyperglycemia, LDL-c >/=100 mg/dL for hyperlipidemia, and SBP >/=130 mmHg for hypertension. Poor adherence was defined as medication gaps for >/=20% of days covered for all medications for each condition separately. Treatment intensification was defined as an increase in the number of drug classes, increased dosage of a class, or a switch to a different class within the 3 months before or after notation of above target levels. RESULTS: Poor adherence was found in 20-23% of patients across the 3 conditions. No evidence of poor adherence with no treatment intensification was found in 30% of hyperglycemiapatients, 47% of hyperlipidemiapatients, and 36% of hypertensionpatients. Poor adherence or lack of therapy intensification was evident in 53-68% of patients above target levels across conditions. CONCLUSIONS: Both nonadherence and lack of treatment intensification occur frequently in patients above target for CVD risk factor levels; however, lack of therapy intensification was somewhat more common. Quality improvement efforts should focus on these modifiable barriers to CVD risk factor control.
Authors: Manel Pladevall; L Keoki Williams; Lisa Ann Potts; George Divine; Hugo Xi; Jennifer Elston Lafata Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Richard Grant; Alyce S Adams; Connie Mah Trinacty; Fang Zhang; Ken Kleinman; Stephen B Soumerai; James B Meigs; Dennis Ross-Degnan Journal: Diabetes Care Date: 2007-01-26 Impact factor: 19.112
Authors: Andrew J Karter; Howard H Moffet; Jennifer Liu; Melissa M Parker; Ameena T Ahmed; Assiamira Ferrara; Joe V Selby Journal: Am J Manag Care Date: 2005-04 Impact factor: 2.229
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Umesh N Khot; Monica B Khot; Christopher T Bajzer; Shelly K Sapp; E Magnus Ohman; Sorin J Brener; Stephen G Ellis; A Michael Lincoff; Eric J Topol Journal: JAMA Date: 2003-08-20 Impact factor: 56.272
Authors: Mohammed K Ali; Kavita Singh; Dimple Kondal; Raji Devarajan; Shivani A Patel; Roopa Shivashankar; Vamadevan S Ajay; A G Unnikrishnan; V Usha Menon; Premlata K Varthakavi; Vijay Viswanathan; Mala Dharmalingam; Ganapati Bantwal; Rakesh Kumar Sahay; Muhammad Qamar Masood; Rajesh Khadgawat; Ankush Desai; Bipin Sethi; Dorairaj Prabhakaran; K M Venkat Narayan; Nikhil Tandon Journal: Ann Intern Med Date: 2016-07-12 Impact factor: 25.391
Authors: Ana H Traylor; Julie A Schmittdiel; Connie S Uratsu; Carol M Mangione; Usha Subramanian Journal: Health Serv Res Date: 2010-03-10 Impact factor: 3.402
Authors: Usha Subramanian; Julie A Schmittdiel; Neha Gavin; Ana Traylor; Connie S Uratsu; Joeseph V Selby; Carol M Mangione Journal: J Gen Intern Med Date: 2009-07-15 Impact factor: 5.128
Authors: Jennifer Elston Lafata; Andrew J Karter; Patrick J O'Connor; Heather Morris; Julie A Schmittdiel; Scott Ratliff; Katherine M Newton; Marsha A Raebel; Ram D Pathak; Abraham Thomas; Melissa G Butler; Kristi Reynolds; Beth Waitzfelder; John F Steiner Journal: J Gen Intern Med Date: 2016-02 Impact factor: 5.128
Authors: Ariel T Holland; Beinan Zhao; Eric C Wong; Sarah E Choi; Nathan D Wong; Latha P Palaniappan Journal: J Diabetes Complications Date: 2012-10-11 Impact factor: 2.852
Authors: Wayne Katon; Joan Russo; Elizabeth H B Lin; Susan R Heckbert; Andy J Karter; Lisa H Williams; Paul Ciechanowski; Evette Ludman; Michael Von Korff Journal: Psychosom Med Date: 2009-10-15 Impact factor: 4.312